Latest News

Semaglutide: Double-edged Sword with Risks and Benefits

A. Cardioprotective Effect The SUSTAIN-6 trial provided compelling evidence for the cardiovascular benefits of semaglutide, demonstrating a 26% reduction in the risk of major adverse cardiovascular eve. ..

14 August 2025

• 
  14 August 2025

  Concerns with Semaglutide and Other GLP-1 Receptor Agonists
• 
  14 August 2025

  Targeting GLP-1 in the brain could transform obesity treatment
• 
  14 August 2025

  GLP-1 medicines and what they are used for

News & media

• 
  Physiology of GLP-1 and its role in the pathophysiology of type 2 diabetes
  14 August 2025
• 
  Weight loss drug semaglutide may reduce alcohol cravings, heavy drinking and smoking, new study finds
  13 August 2025
• 
  How Estrogen Affects Osteoporosis and Bone Health
  15 November 2023
• 
  What to Know About Zepbound (Tirzepatide), the New Mounjaro-Like Weight Loss Drug
  14 November 2023
• 
  Advancements In Peptide Synthesis Technologies
  14 November 2023
• 
  Semaglutide Cuts Risk of Major Cardiovascular Events in Type 2 Diabetes: SUSTAIN-6
  14 November 2023
• 
  Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication
  14 November 2023
• 
  The Global Market Landscape For Peptide Drug Conjugates
  14 November 2023
• 
  Could Diversity in Clinical Trials Be the Key to Understanding Liver Disease?
  2 November 2023
• 
  Semaglutide helps reduce risk of heart attack, stroke in people without diabetes, study finds
  2 November 2023
• 
  Semaglutide ‘A New Pathway’ to CVD Risk Reduction: SELECT
  2 November 2023
• 
  Semaglutide reduces cardiovascular events by 20% in overweight or obese adults who don’t have diabetes: Trial
  2 November 2023